1-phenyl-indoline-2,3-dione-3-oxime | 28150-90-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-phenyl-indoline-2,3-dione-3-oxime
• 英文别名: 1-Phenyl-indolin-2,3-dion-3-oxim；(3E)-3-hydroxyimino-1-phenylindol-2-one
• CAS: 28150-90-5
• 化学式: C₁₄H₁₀N₂O₂
• 分子量: 238.246
• InChiKey: RQNYRJISJDNUOP-FYWRMAATSA-N

物化性质

• 熔点：
  219.0-221.0 °C
• 沸点：
  443.0±28.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.54
• 重原子数：
  18.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.9
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  1-phenyl-indoline-2,3-dione-3-oxime 在 盐酸 、 tin(ll) chloride 作用下， 生成 3-amino-1-phenyl-indolin-2-one
  参考文献：
  名称：

  Langenbeck et al., Justus Liebigs Annalen der Chemie, 1932, vol. 499, p. 201,206

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯-N,N-二苯基乙酰胺 在 三氯化铝 、 乙醇 、 sodium ethanolate 作用下， 生成 1-phenyl-indoline-2,3-dione-3-oxime
  参考文献：
  名称：

  Stolle et al., Journal fur praktische Chemie (Leipzig 1954), 1930, vol. <2>128, p. 1,23

  摘要：

  DOI：

文献信息

• Use of isatin derivatives as ion channel activating agents
  申请人：NeuroSearch A/S

  公开号：US20030114513A1

  公开（公告）日：2003-06-19

  The present invention relates to ion channel activating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as openers of SKCa and IKCa channels. In further aspects, the present invention relates to the use of these SK/IK channel activating agents for the manufacture of medicaments and pharmaceutical compositions comprising the SK/IK channel activating agents. The SK/IK channel activating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK channels, in particular respiratory diseases such as asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

  本发明涉及离子通道激活剂。更具体地，本发明涉及一类特定的化学化合物，已被证明可作为SKCa和IKCa通道的开放剂。在进一步的方面，本发明涉及使用这些SK/IK通道激活剂制造药物和药物组合物。本发明的SK/IK通道激活剂对于治疗或缓解与SK/IK通道相关的疾病和症状具有用处，特别是呼吸道疾病，如哮喘、囊性纤维化、慢性阻塞性肺疾病和流涕、惊厥、血管痉挛、冠状动脉痉挛、肾脏疾病、多囊肾病、膀胱痉挛、尿失禁、膀胱出口梗阻、肠易激综合症、胃肠功能障碍、分泌性腹泻、缺血、脑缺血、缺血性心脏病、心绞痛、冠心病、创伤性脑损伤、精神病、焦虑、抑郁症、痴呆、记忆和注意力缺陷、阿尔茨海默病、痛经、嗜睡病、雷诺氏病、间歇性跛行、Sjogren综合症、偏头痛、心律失常、高血压、失神发作、肌萎缩性肌病、口干症、2型糖尿病、高胰岛素血症、早产、秃发、癌症和免疫抑制等。
• Isatine derivatives, their preparation and use
  申请人：NEUROSEARCH A/S

  公开号：EP0432648A2

  公开（公告）日：1991-06-19

  A method of treatment with compounds having the formula wherein R¹ is hydrogen, C₁₋₆-alkyl which may be branched, C₃₋₇-cycloalkyl, benzyl, phenyl which may be substituted, acyl, hydroxy, C₁₋₆-alkoxy, CH₂CO₂R' wherein R' is hydrogen or C₁₋₆-alkyl which may be branched, CH₂CN, CH₂CONRIVRV wherein RIV and RV independently are hydrogen or C₁₋₆-alkyl, or CH₂C(=NOH)NH₂; R² is hydrogen, benzyl, C₁₋₆-alkyl which may be branched, or C₃₋₇-cycloalkyl; R⁴, R⁵, R⁶, R⁷ independently are hydrogen, C₁₋₆-alkyl which may be branched, phenyl, halogen, C₁₋₆-alkoxy, NO₂, CN, SO₂NR''R''' wherein R'' and R''' independently are hydrogen or C₁₋₆-alkyl, or CF₃; or R⁶ and R⁷ together form an additional 4 to 7 membered ring which may be aromatic or partial saturated and which may be substituted with halogen, NO₂, CF₃, CN, SO₂NR''R''' wherein R'' and R''' independently are hydrogen or C₁₋₆-alkyl, and R⁴ and R⁵ have the meanings set forth above, are disclosed, as well as pharmaceutical compositions thereof. Certain of the compounds are novel. The compounds and pharmaceutical compositions containing the compounds are useful in the treatment of central nervous system disorders and especially conditions sensitive to excitatory amino acids.

  一种用具有以下式子的化合物进行处理的方法 其中 R¹ 是氢、C₁₋₆-烷基（可以是支链）、C₃₋₇-环烷基、苄基、苯基（可以是取代的）、酰基、羟基、C₁₋₆-烷氧基、CH₂CO₂R'，其中 R' 为氢或 C₁₋₆- 烷基（可为支链）、CH₂CN、CH₂CONRIVRV，其中 RIV 和 RV 独立地为氢或 C₁₋₆- 烷基，或 CH₂C(=NOH)NH₂； R² 是氢、苄基、C₁₋₆-烷基（可以是支链）或 C₃₋₇-环烷基； R⁴、R⁵、R⁶、R⁷各自为氢、C₁₋₆-烷基（可为支链）、苯基、卤素、C₁₋₆-烷氧基、NO₂、CN、SO₂NR''R'''（其中 R'' 和 R''' 各自为氢或 C₁₋₆-烷基）或 CF₃；或 R⁶ 和 R⁷ 共同形成另外一个 4 至 7 个成员的环，该环可以是芳香族或部分饱和环，可以被卤素、NO₂、CF₃、CN、公开了 SO₂NR''R'''，其中 R'' 和 R''' 独立地为氢或 C₁₋₆ 烷基，且 R⁴ 和 R⁵ 具有上述含义，还公开了其药物组合物。其中某些化合物是新颖的。 这些化合物和含有这些化合物的药物组合物可用于治疗中枢神经系统疾病，特别是对兴奋性氨基酸敏感的疾病。
• EP0611301A4
  申请人：——

  公开号：EP0611301A4

  公开（公告）日：1993-03-01
• CHELATOR COMPOSITIONS COMPRISING OXIME COMPOUNDS
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0611301A1

  公开（公告）日：1994-08-24
• US5198461A
  申请人：——

  公开号：US5198461A

  公开（公告）日：1993-03-30